Skip to main content
Clinical Trials/NCT00935610
NCT00935610CompletedPhase 2

Effect of the Cysteine-rich Whey Protein Isolate (Immunocal®) in Combination With Physical Exercise on Muscle Function, Body Composition and Inflammatory Cytokine Levels in Elderly Persons: A Randomized, Double-blind Study

Immunotec Inc.1 site in 1 country99 target enrollmentStarted: June 1, 2009Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
99
Locations
1
Primary Endpoint
The mean of percent change in muscle strength based on leg press and chest press evaluation assessed by resistance training equipment

Study Overview

Brief Summary

Aging is typically associated with a decrease in skeletal muscle mass and muscle function, which contributes decisively to disability in old age and to the loss of quality of life.Resistance exercise can increase muscle strength, function and mass in older adults.

The primary aim of this study is to determine whether the combination of resistance training with a supplementation of a cysteine- rich whey protein isolate (Immunocal) compared to combination of resistance training with casein used as control (casein contains little cysteine) could have the potential to provide a synergic beneficial impact on muscle mass and function which could translate to an improved quality of life in elderly persons.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Health Services Research
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
65 Years to — (Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Age 65 or older
  • •Estimated GFR above 45ml/min
  • •Total bilirubin in the normal range (0.2 to 1.2 mg/dl) AST (10-35 U/L for women and 10-50 U/L for men). ALT equal to or less than 2.5 times the upper limit of normal
  • •BMI between 18.5-29.9 (kg)/m2
  • •Sedentary (< 2 hours of structured exercise)in the last 2 or 3 months
  • •Based on investigator judgment according to current Canadian guidelines, medical conditions such as hypertension, diabetes and hyperlipidemia have to be stable and optimally controlled before the subject starts the study.

Exclusion Criteria

  • •History of angioedema or allergic reactions to any compound used in this study.
  • •Milk protein intolerance
  • •Subjects currently using N-acetylcysteine, alpha-lipoic acid supplements, or dry whey protein supplements.
  • •Major surgery in the year prior to testing
  • •Acute coronary or vascular event within the last year or progressive angina
  • •Stroke within the past 2 years
  • •Neurologist and/or orthopedic limitations
  • •Uncontrolled thyroid or pituitary disease
  • •Medication which has a major affect on cognitive function
  • •Signs of early dementia as assessed by Mini-Mental State Examination
  • •Weight loss of more than 4kg(or more than 5% body weight) over last 6 months
  • •Alcohol abuse
  • •Medication which interferes with muscle mass i.e. (corticosteroids)
  • •Any life threatening conditions based on Investigator judgment.
  • •Subjects with allergies/intolerance to soya.
  • •Subjects currently undergoing immunosuppressive therapy.

Arms & Interventions

Immunocal

Active Comparator

20g of Immunocal

Intervention: Immunocal (Dietary Supplement)

Casein

Placebo Comparator

20g of Casein

Intervention: Immunocal (Dietary Supplement)

Immunocal

Active Comparator

20g of Immunocal

Intervention: Casein (Dietary Supplement)

Casein

Placebo Comparator

20g of Casein

Intervention: Casein (Dietary Supplement)

Outcomes

Primary Outcomes

The mean of percent change in muscle strength based on leg press and chest press evaluation assessed by resistance training equipment

Time Frame: 45, 90, 135 days

Secondary Outcomes

  • The mean of percent change in muscle strength based on hand-grip dynamometer(45, 90 and 135 days)
  • The clinical assessment of subject performance status (Quality of life and cognition, Physical Performance Test (PPT)).(40, 90 and 135 days)
  • Insulin sensitivity evaluated by fasting plasma glucose and insulin (HOMA-IR model).(40, 90 and 135 days)
  • Bone mass density(40, 90 and 135 days)
  • 6-min walk test(40, 90 and 135 days)
  • The % change in body weight.(40, 90 and 135 days)
  • Percent change in lean body mass evaluated by DEXA.(40, 90 and 135 days)
  • The change in the plasma concentrations of Tumor Necrosis Factor-alpha (TNF-alpha), interleukin-6 (IL-6), C-reactive protein (CRP), glutathione, cysteine, asparagine, leucine and albumin(40, 90 and 135 days)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials